Overview

A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.

Status:
ENROLLING_BY_INVITATION
Trial end date:
2027-07-19
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of QY201 tablets in the treatment of adult patients with moderate to severe atopic dermatitis (AD).
Phase:
PHASE3
Details
Lead Sponsor:
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.